Roots Analysis

MAY 21, 2024

Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Manufacturing Process : Small Molecules: Manufactured through chemical synthesis, small molecule drugs can be consistently reproduced with a high degree of purity and stability.

Development 97

Development Drugs Manufacturing Immune Response 97

Roots Analysis

MARCH 2, 2022

However, it is important to highlight that there are still several challenges which need to be addressed in order to develop biologic drugs capable of effectively being administered via the oral route without undergoing significant losses in specificity and / or bioavailability. Oral Protein / Peptide-based Drugs.

Protein 52

Protein Drugs Drug Delivery Drug Delivery Systems 52

pharmaphorum

JANUARY 16, 2023

The bi-weekly intramuscular shot – which was also approved in China in 2021 – will enter a crowded market for long-acing injectable (LAI) schizophrenia therapies in the US and have to take on heavyweight competition, including drugs that require less frequent dosing.

FDA Approval 52

FDA Approval Drugs Bioavailability Marketing 52

Roots Analysis

MARCH 1, 2022

Interestingly, over the past few years, drug developers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Bioavailability 52

XTalks

DECEMBER 5, 2022

Clinical-stage biotech company PureTech Health has announced it has developed a new oral CBD therapeutic candidate with improved bioavailability and tolerability, which could expand use of the CBD prodrug in a wide range of indications and age groups. Jazz bought out Epidiolex developer GW Pharmaceuticals for the drug in a whopping $7.2

Bioavailability 79

Bioavailability FDA Approval Trials Drugs 79

Pharmaceutical Technology

NOVEMBER 24, 2022

Understanding how a drug will act in the body, including how it is absorbed, distributed, and eventually eliminated, is a crucial component of drug research. ADME studies require the use of a radiolabeled version of the investigational drug. ADME studies require the use of a radiolabeled version of the investigational drug.

Bioavailability 130

Bioavailability Manufacturing Drugs Production 130

Pharmaceutical Technology

JUNE 26, 2022

Drug substance plays a key part in ensuring a drug program achieves its major milestones, keeps to budget and delivers on its corporate goals. To increase the likelihood of clinical success, drug developers must identify challenges and potential red flags early on in the candidate selection stage. Polymorphic form issues.

Manufacturing 130

Manufacturing Drugs Production Development 130

Roots Analysis

OCTOBER 2, 2023

Owing to their unique size and physicochemical properties ( surface roughness, surface area, surface energy, crystal structure and shape ), nanoparticles can be widely used as a contrasting agent in medical imaging, a vesicle to cross the blood-brain barrier and a carrier for targeted delivery of genes / drugs, proteins, vaccines and antibiotics.

Drug Delivery 40

Drug Delivery Drugs Bioavailability Development 40

Roots Analysis

FEBRUARY 20, 2022

Over the last decade, one of the major challenges faced by pharmaceutical players across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Nanoparticles Contract Manufacturing. Web: [link].

Contract Manufacturing 52

Contract Manufacturing Bioavailability Manufacturing Drug Delivery Systems 52

pharmaphorum

AUGUST 19, 2022

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of opioid drugs. If all goes well, the aim is to bring resiniferatoxin to market in 2025.

Drugs 52

Drugs Bioavailability Trials Clinical Development 52

Delveinsight

SEPTEMBER 8, 2021

The exact cause of SLE is unknown; however, factors such as sunlight and drugs may precipitate the condition, and many studies have revealed a complex genetic basis. The first line of therapy/agents recommended for the Systemic Lupus Erythematosus treatment includes Nonsteroidal anti-inflammatory drugs (NSAIDs) (Naproxen, Celecoxib, etc.),

Marketing 52

Marketing Sales FDA Approval Antibody 52

Camargo

DECEMBER 22, 2021

Informed by today’s competitive drug development landscape, as well as by the sponsor’s strategic goals and capabilities, a portfolio analysis involves assessing product concept and differentiation, strategic planning, factoring in unmet patient needs, and estimating timelines and expenses. Fine-Tuning Strategic Assessment.

Bioequivalency 169

Bioequivalency Production Genotoxicity In-Vivo 169

Delveinsight

FEBRUARY 16, 2021

Numerous immunotherapy-based combinations are already trying in the old game of gleek to stake up some share in previously untreated, metastatic kidney cancer; however, the market seems to expand as the new entrants continue to make their entry. Chemotherapy drugs while killing cancer cells also damages normal tissues.

Marketing 52

Marketing Protein Bioavailability Drugs 52

The Pharma Data

JANUARY 7, 2021

While oral delivery route (62%) is still the most prevalent amongst marketed drug products, alternative adminstrations such as injection (22%), cutaneous, mucosal, inhalation, and others are making up a greater percentage as the industry works to improve bioavailability and subsequent efficacy.

Bioavailability 52

Bioavailability Production Manufacturing Drugs 52

pharmaphorum

FEBRUARY 25, 2021

Chiesi and Protalix have built the case for their long-acting enzyme replacement therapy (ERT) for Fabry disease PRX-102, as the FDA’s review of the drug continues towards a decision due by 27 April. . The post Switch data back Chiesi/Protalix long-acting Fabry drug appeared first on.

Drugs 80

Drugs Bioavailability Antibody Marketing 80

Pharmaceutical Technology

OCTOBER 25, 2022

Understanding both the significant competitive advantages that FDC products can offer, and the difficulties and potential pitfalls associated with development and manufacturing of FDC drugs in oral solid dosage forms is a critical first step for companies exploring this approach. new FDC products per year. Improved convenience and safety.

Manufacturing 130

Manufacturing Production Packaging Packaging 130

Pharmaceutical Technology

AUGUST 3, 2022

The potential to use these scientific breakthroughs to make a real difference to patients’ lives is what drives many highly skilled scientists to the world of drug development. Yet commercialising a drug is no easy journey, hence why just 10% of new drug candidates succeed in making it to market.

Development 130

Development Production Manufacturing Bioavailability 130

Roots Analysis

SEPTEMBER 1, 2023

By charting new waters and creating uncontested market spaces, companies can differentiate themselves and unlock unprecedented growth opportunities. In this blog post, I’ll explore how pharma / biotech companies can leverage the blue ocean and red ocean strategy to make waves in the market.

Drug Delivery 52

Drug Delivery Marketing Drug Delivery Systems Drugs 52

The Pharma Data

DECEMBER 9, 2020

Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets,” Feinberg said at the time of the launch. It’s like taking out the trash. Tranquis Therapeutics.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

DECEMBER 3, 2020

(TWO: 4162) announced today that it has entered into a Collaboration and License Agreement with UK-based Sentinel Oncology Limited for advancing the new drug development of SOL-578 , a Checkpoint Kinase 1 (Chk1) inhibitor, under which PharmaEngine will fund the IND enabling studies for SOL-578. ” About SOL-578. PharmaEngine, Inc.

Licensing 52

Licensing Licensing Bioavailability DNA 52

Pharmaceutical Technology

AUGUST 22, 2022

They also offer enhanced bioavailability, exact dosing and an extended shelf life. Softgels have now achieved strong recognition in the prescription, consumer health and supplements markets. Fixed-dose combination (FDC) systems aim to increase patient compliance in therapies involving two or more active drugs.

Compliance 130

Compliance Bioavailability Containment Branding 130

Pharmaceutical Technology

JANUARY 25, 2023

They provide a higher ability to regulate protein levels and can affect the non-enzymatic function of the protein while also providing an alternative to targeting drug-resistant proteins for overcoming tumour drug resistance.

Protein 130

Protein Bioavailability Development Scientist 130

Roots Analysis

MARCH 13, 2022

Given the evident benefits of biologics over small molecule drugs (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is poised to witness continued and consistent growth over the next several years. Future Evolution of Biopharmaceutical Excipient Manufacturing Market.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Delveinsight

AUGUST 10, 2020

Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of IPF and SSc-ILD. In August 2016, nintedanib gained Orphan drug Designation from European Commission to treat systemic sclerosis. Ofev (Nintedanib) Facts. Ofev (Nintedanib) Approval History. In March 2020, The U.S.

Drugs 52

Drugs Trials Bioavailability FDA Approval 52

XTalks

FEBRUARY 3, 2023

The US Food and Drug Administration (FDA) has approved the first and only oral drug for the treatment of advanced or metastatic breast cancer in postmenopausal women or adult men with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) ESR1 mutations. months on elacestrant compared with 1.9

Clinical Trials 81

Clinical Trials Clinical Trials FDA Approval Trials 81

Delveinsight

JULY 30, 2020

The global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 In patients with CALD, Adrenoleukodystrophy market offers two therapies, namely Lorenzo’s oil and haematopoietic stem cell transplantation (HSCT) , using either umbilical cord stem cells or bone marrow stem cells.

Hormones 52

Hormones Marketing Gene Trials 52

Roots Analysis

JANUARY 28, 2024

Pharmaceutical Research: Big data analytics can be applied in various areas of pharmaceutical research, including drug discovery and development, precision medicine , clinical trial optimization, pharmacovigilance and drug safety, supply chain optimization, and real-time monitoring and surveillance.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

XTalks

MAY 23, 2024

Drugs such as pembrolizumab (Merck’s Keytruda) and nivolumab (Bristol Myers Squibb’s Opdivo) have revolutionized the treatment options for skin cancer. Dr. Bokhari: Medicus Pharma, through its subsidiary SkinJect, addresses these needs with its innovative transdermal drug delivery system (TDDS). 10), AbbVie Inc. (#11)

Life Science 72

Life Science Dermatology Drug Delivery Systems Medicine 72

The Pharma Data

NOVEMBER 11, 2020

Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. While SLV213 can be dosed orally or intravenously, Selva is first advancing it as an oral drug candidate for COVID-19. About SLV213.

Protein 52

Protein Bioavailability Development Drugs 52

XTalks

AUGUST 30, 2022

According to an analysis of the 2013 Medical Expenditure Panel Survey, one in six US adults reported taking a psychiatric drug at least once in 2013. CNS drugs treat a range of neurologic and psychiatric disorders, such as psychosis, depression, Parkinson’s disease, multiple sclerosis and epilepsy.

Trials 83

Trials Drug Delivery Drugs Gene 83

XTalks

SEPTEMBER 24, 2024

Incorporating Patient and Caregiver Feedback Marinus Pharmaceuticals places a high value on patient and caregiver feedback, integrating it into every stage of drug development to ensure their treatments are both scientifically sound and practically beneficial. Dr. Flatt emphasized the importance of understanding patient needs from the start.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Development 52

The Pharma Data

NOVEMBER 26, 2020

As drug molecules become more complex so do the options to deliver them. This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. HELSINKI , Nov. ” Prof.

Containment 52

Containment Medicine Development Bioavailability 52

Delveinsight

JANUARY 7, 2021

Ikena secures USD 120 Million to advance a growing pipeline of cancer drugs. Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The newer side of the pipeline points targeted oncology drugs. Terns raises USD 87 Million for NASH drugs. IND-enabling studies are underway.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

The Pharma Data

DECEMBER 3, 2020

Food and Drug Administration and European Medicines Agency as we work to bring maribavir to patients.”. Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. About Maribavir.

Drugs 52

Drugs Medicine Trials Development 52

The Pharma Data

JANUARY 3, 2021

The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules’ formulation performance through its nanoforming services. . +46 7686 650 11. 2 Proof of Concept.

Containment 52

Containment Bioavailability Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 20, 2021

Part B is designed to be a confirmatory post-market approval observational trial to confirm long-term renal protection and assess the difference in kidney function between treated and placebo patients as measured by eGFR over a two-year period from the start of dosing of each patient. It also showed that Nefecon was generally well-tolerated.

Trials 52

Trials Containment Clinical Trials Clinical Trials 52